CMR phenotype tied to higher heart failure and arrhythmia risk in cardiac sarcoidosis patients: JAMA
Minnesota: A recent study has shown that a cardiovascular magnetic resonance (CMR) phenotype involving pathology-frequent late gadolinium enhancement (LGE) features were tied to a high risk of heart failure and arrhythmic events in sarcoidosis patients."Even in the presence of LGE or unusual left ventricular ejection fraction (LVEF), the absence of the pathology-frequent LGE phenotype was...
Minnesota: A recent study has shown that a cardiovascular magnetic resonance (CMR) phenotype involving pathology-frequent late gadolinium enhancement (LGE) features were tied to a high risk of heart failure and arrhythmic events in sarcoidosis patients.
"Even in the presence of LGE or unusual left ventricular ejection fraction (LVEF), the absence of the pathology-frequent LGE phenotype was linked to a low risk of arrhythmic events," Pal Satyajit Singh Athwal, Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, and colleagues wrote in their study.
The study's findings, published in JAMA Cardiology, imply that CMR phenotypes could help optimize clinical decision-making for treatment options, namely implantable cardioverter-defibrillators.
In sarcoidosis patients with suspected heart involvement, LGE on cardiac MRI imaging identifies patients at an increased risk of adverse outcomes. However, only a minority of patients with LGE experience these outcomes, and recognizing this subgroup may improve outcomes and treatment in these patients.
Considering the above, the research team aimed to assess whether CMR phenotypes based on LVEF and LGE in patients with doubtful cardiac sarcoidosis (CS) are linked with adverse outcomes during follow-up in a cohort study.
The study included consecutive patients with histologically proven sarcoidosis who underwent CMR to diagnose suspected CS from 2004 to 2020. They were followed for a median of 4.3 years at an academic medical center in Minnesota. Collection of medical history, demographic data, comorbidities, outcome data, and medications was done blinded to CMR data.
Based on the presence and features of LVEF and LGE, CMR phenotypes were identified. Classification of LGE was done as pathology-frequent or pathology-rare based on the frequency of cardiac damage features in assessing gross pathology of the heart of CS patients who had a sudden cardiac death or cardiac transplant.
Among 504 patients (mean age, 54.1 years; 48.0% female and 52.0% male), identification of 4 distinct CMR phenotypes was done: normal LVEF and no LGE (n = 290; 57.5%), pathology-frequent LGE (n = 103; 20.4%), abnormal LVEF and no LGE (n = 53; 10.5%), and pathology-rare LGE (n = 58; 11.5%).
Based on the research, the authors reported the following:
- The phenotype with pathology-frequent LGE was tied to a high risk of arrhythmic events (hazard ratio [HR], 12.12) independent of LVEF and the extent of left ventricular late gadolinium enhancement (LVLGE).
- Also, it was associated with a high risk of heart failure events (HR, 2.49) independent of age, LVEF, pulmonary hypertension, right ventricular ejection fraction, and LVLGE extent. The risk of arrhythmic events was more significant with a rising number of pathology-frequent LGE features.
- The absence of the pathology-frequent LGE phenotype was linked with a low incidence of arrhythmic events, even with LGE or abnormal LVEF.
"The findings showed that a CMR phenotype involving pathology-frequent LGE features was linked with a high incidence of arrhythmic and heart failure events in sarcoidosis patients," the researchers wrote.
"The findings suggest that CMR phenotypes could be used to optimize clinical decision-making for treatment options, such as implantable cardioverter-defibrillators," they concluded.
Athwal PSS, Chhikara S, Ismail MF, et al. Cardiovascular Magnetic Resonance Imaging Phenotypes and Long-term Outcomes in Patients With Suspected Cardiac Sarcoidosis. JAMA Cardiol. Published online September 14, 2022. doi:10.1001/jamacardio.2022.2981
Medha, MSc. Biotechnology
Medha Baranwal joined Medical Dialogues as an Editor in 2018 for Speciality Medical Dialogues. She covers several medical specialties including Cardiac Sciences, Dentistry, Diabetes and Endo, Diagnostics, ENT, Gastroenterology, Neurosciences, and Radiology. She has completed her Bachelors in Biomedical Sciences from DU and then pursued Masters in Biotechnology from Amity University. She has a working experience of 5 years in the field of medical research writing, scientific writing, content writing, and content management. She can be contacted at email@example.com. Contact no. 011-43720751